Surgical outcomes and prognosis of non-small-cell lung cancer in patients with chronic lung diseases: a retrospective analysis

被引:9
|
作者
Choi, Soohwan [1 ]
Park, Jaekil [2 ]
机构
[1] Catholic Univ Korea, Dept Thorac & Cardiovasc Surg, St Vincents Hosp, 93 Jungbudae Ro, Suwon 16247, Gyeonggi Do, South Korea
[2] Catholic Univ Korea, Dept Thorac & Cardiovasc Surg, Seoul St Marys Hosp, Seoul, South Korea
关键词
Lung cancer; Chronic obstructive pulmonary disease; Interstitial lung disease; Combined pulmonary fibrosis and emphysema; COMBINED PULMONARY-FIBROSIS; EMPHYSEMA; SMOKING; TERM; PREVALENCE; RESECTION; SURVIVAL; IMPACT; COPD;
D O I
10.1093/ejcts/ezaa060
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES: Lung cancer treatment in patients with chronic lung diseases is challenging because postoperative care is difficult and surgical outcomes are poorer than in patients with healthy lungs. This study aimed to examine postsurgical outcomes of patients with comorbid lung diseases treated for lung cancer. METHODS: This retrospective study enrolled 1526 patients who underwent curative surgical resection for non-small-cell lung cancer at a single centre between October 2008 and April 2017. Based on computed tomography findings, patients were assigned to 4 groups and their demographic characteristics, clinicopathological features, surgical outcomes and survival were compared. RESULTS: There were 1101 patients in group A, 266 patients in group B, 62 patients in group C and 97 patients in group D. In the chronic lung disease groups (B, C and D), there was a high percentage of smoking history (86.5%, 79.0% and 92.8%, respectively; P<0.01). The occurrence rate of postoperative lung complications and operative mortality rates were higher in patients with chronic lung disease. Groups A, B, C and D contained 819 (74.4%), 159 (59.8%), 43 (69.4%) and 65 (67.0%) stage I patients, respectively (P<0.01). The groups showed significant differences in overall survival and disease-free survival (all P<0.01). The presence of combined pulmonary fibrosis and emphysema was the only significant negative prognostic factor for overall survival. CONCLUSIONS: The presence of comorbid chronic lung diseases might negatively affect prognosis in patients with non-small-cell lung cancer. The presence of combined pulmonary fibrosis and emphysema could be a negative prognostic factor in lung cancer treatment.
引用
收藏
页码:357 / 364
页数:8
相关论文
共 50 条
  • [41] Non-small-cell lung cancer
    Gridelli, Cesare
    Rossi, Antonio
    Carbone, David P.
    Guarize, Juliana
    Karachaliou, Niki
    Mok, Tony
    Petrella, Francesco
    Spaggiari, Lorenzo
    Rosell, Rafael
    NATURE REVIEWS DISEASE PRIMERS, 2015, 1
  • [42] Non-small-cell lung cancer
    不详
    NATURE REVIEWS DISEASE PRIMERS, 2024, 10 (01):
  • [44] Non-small-cell lung cancer
    Goldstraw, Peter
    Ball, David
    Jett, James R.
    Le Chevalier, Thierry
    Lim, Eric
    Nicholson, Andrew G.
    Shepherd, Frances A.
    LANCET, 2011, 378 (9804): : 1727 - 1740
  • [45] Analysis of the Significance of Immune Cell Infiltration and Prognosis of Non-Small-Cell Lung Cancer by Bioinformatics
    Sun, Heng
    Sui, Bowen
    Li, Yu
    Yan, Jun
    Cao, Mingming
    Zhang, Lijia
    Liu, Songjiang
    JOURNAL OF HEALTHCARE ENGINEERING, 2021, 2021
  • [46] Treatment and prognosis of advanced stage non-small-cell lung cancer
    Ben Abdallah, F. Chermiti
    Ben Ali, G.
    Boudaya, M. Sadok
    Mlika, M.
    Chtourou, A.
    Taktak, S.
    Ben Kheder, A.
    REVUE DES MALADIES RESPIRATOIRES, 2014, 31 (03) : 214 - 220
  • [47] Retrospective analysis of a group of patients with advanced Non-Small-Cell lung cancer (NSCLC) treated with Gefitinib
    Bandera, M.
    Bascialla, L.
    Martinelli, B.
    Masera, G. L. Rodolfo
    Vallini, I.
    Zanlorenzi, L.
    Pinotti, G.
    ANNALS OF ONCOLOGY, 2005, 16 : 25 - 25
  • [48] Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer
    Sugano, Teppei
    Seike, Masahiro
    Saito, Yoshinobu
    Kashiwada, Takeru
    Terasaki, Yasuhiro
    Takano, Natsuki
    Hisakane, Kakeru
    Takahashi, Satoshi
    Tanaka, Toru
    Takeuchi, Susumu
    Miyanaga, Akihiko
    Minegishi, Yuji
    Noro, Rintaro
    Kubota, Kaoru
    Gemma, Akihiko
    THORACIC CANCER, 2020, 11 (04) : 1052 - 1060
  • [49] Results of a Surgical Resection for Patients With Stage IV Non-Small-Cell Lung Cancer
    Hanagiri, Takeshi
    Takenaka, Masaru
    Oka, Soich
    Shigematsu, Yoshiki
    Nagata, Yoshika
    Shimokawa, Hidehiko
    Uramoto, Hidetaka
    Tanaka, Fumihiro
    CLINICAL LUNG CANCER, 2012, 13 (03) : 220 - 224
  • [50] Amrubicin for non-small-cell lung cancer and small-cell lung cancer
    Kurata, Takayasu
    Okamoto, Isamu
    Tamura, Kenji
    Fukuoka, Masahiro
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (05) : 499 - 504